Health‐related quality of life · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · participants with severe alcoholic hepatitis
It is very uncertain whether pentoxifylline changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with severe alcoholic hepatitis
It is very uncertain whether pentoxifylline changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with severe alcoholic hepatitis
It is very uncertain whether pentoxifylline changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number) · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · participants with alcoholic hepatitis (all severity)
It is very uncertain whether pentoxifylline changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether pentoxifylline changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether pentoxifylline changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Albumin plus midodrine plus octreotide plus pentoxifylline (No RCTs) · people with hepatorenal syndrome with decompensated liver cirrhosis
It is very uncertain whether the intervention changes albumin plus midodrine plus octreotide plus pentoxifylline (No RCTs) (very low certainty).
1 finding from 1 review
HR 0.5 [0.06, 4.07]
Studies not reported
Very low